TFRC and neoplasm: Targeting of tumor cells is achieved through the abilities of the transferrin receptor 1 (TfR1) and the Scavenger Receptor Class A Member 5 (SCARA5), overexpressed in cancer cells [19,36] to recognize APO nanocages.